Medical Devices Rules 2017 (G.S.R. 78(E)): Structure and Amendments

1. Key takeaways

The basic law for medical devices in India is the Medical Devices Rules, 2017 (MDR 2017), notified as G.S.R. 78(E), published in the Gazette of India on 31 January 2017, with the device-related provisions in force from 1 January 2018. The Rules were made under s.12(1) and s.33(1) of the Drugs and Cosmetics Act, 1940, and comprise 12 chapters, 97 rules, 8 schedules and 40 forms. Any company planning an Indian filing should treat this instrument, together with its amendments, as the single reference framework against which every timeline, fee and obligation in the project is stated. Working from outdated summaries of the original 2017 text is one of the most common and most costly sources of error in Indian regulatory planning.

• MDR 2017 (G.S.R. 78(E)) is the operative device regulation in India.
• It rests on s.12(1) and s.33(1) of the Drugs and Cosmetics Act, 1940.
• Device provisions have applied since 1 January 2018.
• Key amendments of 2022 changed the recognised-country list and Class A treatment.
• Draft amendments still pending must be marked as drafts, not as law in force.

2. Legal basis

The structure of the Rules follows the life cycle of a device, from manufacture through import and labelling to clinical investigation and post-market obligations. The table below maps each working area to its chapter, and lists the schedules that carry the substantive technical content. In practice, the schedules rather than the chapters consume most of the preparation effort, because they define what a dossier must contain and how quality systems and change assessments are judged.

Key amendment chain:

1. G.S.R. 174(E) (in force from 2022-03-04): replaced “or the United States of America” with “United Kingdom or the United States of America”, thereby adding the United Kingdom to the recognised list in Rule 36(3).
2. G.S.R. 777(E) (published 2022-10-14): Class A devices that are non-sterile and non-measuring are exempted from Chapter IV, Chapter V, Chapter VII, Chapter VIII and Chapter XI, and are instead subject to online registration (confirmed by CDSCO official FAQ question 69).
3. G.S.R. 515(E) (signed 2026-06-23, published 2026-06-24, 30-day comment period until 2026-07-22): a draft amendment proposing to shorten manufacturing licence timelines.
4. G.S.R. 883(E) (December 2025): a draft amendment proposing to permit Class A registration numbers to be marked on labels with a “Reg. No.” prefix.

3. Expert insights

Insight one: MDR 2017 is a dedicated device regulation, but the parent statute remains the drugs law of 1940. India has no standalone medical device act. Devices enter the regulatory system only after being notified as drugs under s.3(b)(iv) of the Drugs and Cosmetics Act. This produces a chain consequence that many newcomers underestimate: the penal provisions of the drugs law apply directly to devices. The practical meaning is that device non-compliance in India is not a purely administrative matter, and the severity associated with pharmaceutical offences shapes the enforcement posture that companies actually face in the market.

Insight two: the eight schedules are where the real workload lives. The overwhelming majority of deficiencies and rejections arise on the Fourth Schedule (DMF/PMF), the Fifth Schedule (QMS) and the Sixth Schedule (change assessment), not on the application forms themselves. Teams that budget their effort by counting forms rather than by counting schedule content routinely discover, mid-project, that the technical file is the project. Building the dossier against the schedule requirements from the first day is far cheaper than reconstructing it after a deficiency letter arrives.

Insight three: the pace of amendment is accelerating. There were two amendments in 2022, one draft in 2025 and at least two drafts in 2026. Chinese-language material generally remains stuck at the original 2017 version, with the result that changes from 2022 — the entry of the United Kingdom into the recognised list, and the exemption for eligible Class A devices — have barely propagated correctly in the Chinese-speaking world. Any project document that cannot name the version and amendment numbers it relies on should be treated as unreliable, and any statement of a timeline or fee that cannot be traced to a specific notification should be regarded as a practical estimate pending verification against the current text.

4. Practical recommendations

• GRZAN requires the cover page of every India project dossier to state the version of the Rules and the amendment numbers relied upon, and to be revisited whenever the regulatory base changes.
• Maintain a five-level citation hierarchy internally: parent statute — Rules — schedules — amendments — official FAQ.
• Every timeline, fee or obligation written into a plan must be traceable to a specific notification number; wording such as reportedly or usually has no place in a dossier.
• Check each amendment against the project scope at intake: the UK addition affects clinical evidence strategy, while the Class A exemption may change the entire filing route.
• Flag draft notifications explicitly as drafts, not in force, wherever they are cited, and track their comment periods and expected finalisation separately from binding obligations.

5. Verification checklist

• □ The text cited is the current version of MDR 2017, not the original 2017 text.
• □ G.S.R. 174(E) (United Kingdom added to the list, effective 2022-03-04) has been checked.
• □ G.S.R. 777(E) (Class A exemption, published 2022-10-14) has been checked.
• □ Draft notifications (G.S.R. 515(E), 883(E)) are separately marked as drafts not in force.
• □ Every schedule reference is pinned to a specific schedule number.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of 27 October 2026.